Masimo (MASI) to Release Earnings on Thursday

Masimo (NASDAQ:MASI) is expected to release its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect Masimo to post earnings of $1.41 per share and revenue of $407.9730 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

Masimo Stock Performance

NASDAQ:MASI opened at $175.35 on Wednesday. The firm has a market cap of $9.42 billion, a PE ratio of -16.64, a price-to-earnings-growth ratio of 1.78 and a beta of 1.26. The business has a 50 day moving average price of $140.71 and a 200-day moving average price of $143.43. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.92 and a current ratio of 2.84. Masimo has a fifty-two week low of $125.94 and a fifty-two week high of $194.88.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of MASI. Aigen Investment Management LP acquired a new position in shares of Masimo in the 4th quarter valued at about $262,000. Virtu Financial LLC acquired a new position in Masimo during the fourth quarter worth about $258,000. iSAM Funds UK Ltd grew its holdings in Masimo by 152.1% in the 4th quarter. iSAM Funds UK Ltd now owns 1,762 shares of the medical equipment provider’s stock valued at $229,000 after buying an additional 1,063 shares in the last quarter. O Shaughnessy Asset Management LLC raised its stake in Masimo by 18.1% during the fourth quarter. O Shaughnessy Asset Management LLC now owns 1,762 shares of the medical equipment provider’s stock worth $229,000 after purchasing an additional 270 shares during the period. Finally, Rothschild Wealth LLC purchased a new position in Masimo in the fourth quarter worth approximately $227,000. 85.96% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on MASI shares. BTIG Research cut Masimo from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 18th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Masimo in a research report on Thursday, January 22nd. Wells Fargo & Company downgraded Masimo from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $190.00 to $180.00 in a report on Wednesday, February 18th. Stifel Nicolaus set a $180.00 price target on Masimo in a research report on Tuesday, February 17th. Finally, Needham & Company LLC restated a “hold” rating on shares of Masimo in a research note on Monday, December 1st. One equities research analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $181.17.

Masimo Company Profile

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.